BNR

BNR

Burning Rock Biotech Ltd

Burning Rock Biotech Ltd develops cancer therapy selection tests using next-generation sequencing in China and the U.S., offering tissue and liquid biopsy solutions for various cancers. Its services focus on precision oncology and early detection for patients.

⚕️ Healthcare NASDAQ Listed 2020 ¥ CNY
$1,000 invested 5 years ago $45today

Score Overview

1 Year
Score
Net Growth84.47%
Net TrendGrew
Net Income Consistency
Rev Growth1.75%
Rev TrendGrew
Revenue Consistency
5 Years
Score5.6
Net Growth86.78%
Net Trend60%
Net Income Consistency
Rev Growth22.09%
Rev Trend60%
Revenue Consistency
All Time
Score
Net Growth86.78%
Net Trend60%
Net Income Consistency
Rev Growth22.09%
Rev Trend60%
Revenue Consistency

See the full market ranking →

Burning Rock Biotech Ltd fundamental performance

Between 2020 and 2025, revenue grew from ¥ 429M to ¥ 524M and net income went from -¥ 407M to -¥ 53M. Revenue increased in 3 of those 5 years; net income in 3.

Burning Rock Biotech Ltd currently holds a 5-year HDB Score of 5.6 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 9.93
1 Year2025-08-12
$ 6.9542.88%
5 Years2021-08-12
$ 219.30-95.47%
All Time2020-06-12
$ 246.30-95.97%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2025¥ 524M-¥ 53M¥ 481M
2024¥ 515M-¥ 346M¥ 519M
2023¥ 537M-¥ 653M¥ 615M
2022¥ 563M-¥ 971M¥ 905M
2021¥ 507M-¥ 796M¥ 1.49B
IPO2020¥ 429M-¥ 407M¥ 2.25B

Explore beyond BNR

You're looking at Burning Rock Biotech Ltd. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies